A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study

BACKGROUND: Very few cancer patients were enrolled in coronavirus disease-2019 vaccine studies. In order to address this gap of knowledge, real-world studies are mandatory. The aim of this study was to assess both humoral and cellular response after a messenger RNA vaccination schedule. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Lasagna, A., Agustoni, F., Percivalle, E., Borgetto, S., Paulet, A., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J.C., Ferrari, A., Zavaglio, F., Arena, F., Lilleri, D., Secondino, S., Falzoni, M., Schiavo, R., Klersy, C., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407964/
https://www.ncbi.nlm.nih.gov/pubmed/34543863
http://dx.doi.org/10.1016/j.esmoop.2021.100272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407964/
https://www.ncbi.nlm.nih.gov/pubmed/34543863
http://dx.doi.org/10.1016/j.esmoop.2021.100272

Ejemplares similares